Cytotoxic drugs that show an increased incidence of pulmonary toxicity when combined include carmustine, mitomycin, cyclophosphamide, bleomycin
by WA Al-Jizani 2024 Cited by 5ABSTRACT. Background: Bleomycin pulmonary toxicity (BPT) has been described in Hodgkin's lymphoma (HL) patients treated with bleomycin-
Bleomycin stands out for its high incidence of pulmonary toxicity, affecting up to 10% of patients undergoing treatment. Amiodarone, known for
by AB Simpson 2024 Cited by 196toxicity may exceed 10%. Thebenefits of bleomycin could be questioned for this age group. Keywords: bleomycin; pulmonary toxicity; germ cell tumours. An anti
Imatinib Treatment for Bleomycin-Induced Pulmonary Toxicity The basic treatment for bleomycin-induced pulmonary toxicity is corticosteroids.
Various studies have reported bleomycin pulmonary toxicity (BPT) prevalence of 2-46 %, with a mortality rate of 1-2 % among bleomycin administered patients [9]
Bleomycin stands out for its high incidence of pulmonary toxicity, affecting up to 10% of patients undergoing treatment. Amiodarone, known for
All three developed bleomycin induced pulmonary toxicity in the form of pulmonary fibrosis during treatment of the disease. Mode of treatment, severity of the
The acute pulmonary toxicity of bleomycin has been attributed to DNA strand scission, with resulting chromosomal injury. Animal studies confirm that more chronic bleomycin injury occurs predominantly in the lungs, which have very low levels of bleomycin hydrolase activity.
Yes, CTEPH and all other forms of Pulmonary Hypertension are insidious killers and the men and women who work to treat us are incredible heroes. I include Big Pharma because Bayer Aspirin makes a drug called Adempas, it only works on Pulmonary Arterial Hypertension and CTEPH, two of the rarest conditions on the planet. They lose money with each pill but they make sure we get it. November is Pulmonary Hypertension Awareness Month!